Cytodyn Inc (Cytodyn) is a biotechnology company. It focused on developing treatments in the areas of human immunodeficiency virus (“HIV”), cancer, immunology, and novel coronavirus disease corvid 19. The company provide treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab belongs to a class of HIV therapies known as entry inhibitors which block HIV from entering and infecting specific cells. CytoDyn uses prostate diagnostic test to determine outcomes of patients diagnosed with prostate cancer. It works in collaboration with pharmaceutical and biotechnology companies to develop its products. The company has operational presence in Florida, the US. Cytodyn is headquartered in Vancouver, Washington, the US.

Headquarters United States of America

Address 1111 Main St Ste 660, Vancouver, Washington, 98660-2970


Telephone 1 360 9808524

No of Employees 23

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange CYDY (OTC)

EPS XXX

Net Income (2021) XXX -24.3% (2021 vs 2020)

Market Cap* $348.5M

   

   

* As of and is in US$

Products and Services

Products Services
Leronlimab Treatment of HIV
Treatment of Cancer
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Financing Agreements In April, the company announced to raise US$1.89 million in equity financing.
2022 Contracts/Agreements In January, the company along with Regnum Corp and SevenScore Pharmaceuticals, LLC entered into a commercialization and license Agreement to commercialize leronlimab (PRO 140) in the U.S. for the treatment of HIV from SevenScore to Regnum.
2021 Regulatory Approval In December, the company submitted a Phase 3, randomized, double blind, placebo controlled trial with the U.S. Food and Drug Administration (FDA) for phase 3 Registrational trial of Leronlimab for Critically Ill COVID-19 population.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Cytodyn Inc F. Hoffmann-La Roche Ltd AbbVie Inc Merck & Co Inc Celgene Corp
Headquarters United States of America Switzerland United States of America United States of America United States of America
City Vancouver Basel North Chicago Kenilworth Summit
State/Province Washington - Illinois New Jersey New Jersey
No. of Employees 23 100,920 50,000 68,000 -
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Tanya Durkee Urbach Chairman Executive Board - 54
Scott A. Kelly Head-Business Development; Director; Chief Medical Officer Executive Board 2020 51
Antonio Migliarese Chief Financial Officer Senior Management 2021 38
Nitya G Ray Chief Technology Officer; Head - Process Sciences; Chief Operating Officer Senior Management 2021 69
Cyrus Arman President Senior Management 2022 -
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer